Tissue factor (TF) is a transmembrane glycoprotein that was originally recognized for its ability to initiate the extrinsic pathway of coagulation.
Introduction
Tissue factor (TF) is a transmembrane glycoprotein that is a cofactor for Factor VII (FVII; the active form is denoted by FVIIa) activation and that initiates coagulation [1, 2] . TF forms an envelope that surrounds the vascular tree [3] and thus promotes formation of a fibrin clot in the event of vascular injury. T h e procoagulant function of TF has long been recognized; however, more recently non-haemostatic functions of TF have emerged. T h e TF-FVIIa complex in- where angiogenesis is a key feature of pathogenesis, such as tumour growth and metastasis, myocardial infarction and stroke [29, 30] . We have described previously the ability of a peptide (KRAD14), derived from the apolipoprotein BlOO (apoB100) moiety of low-density lipoprotein (LDL), to inhibit the procoagulant activity of TF via its ability to prevent FVII activation by TF [31] . In this study, we tested the ability of the KRAD14 peptide and an anti-TF antibody (TF85G9) [32] to inhibit the formation of cellular networks in an in vitro model of angiogenesis.
Materials and methods
Materials and cells were obtained from the following sources : T24 human bladder carcinoma cells (European Collection of Animal Cell Cultures, Salisbury, Wiltshire, U.K.), MatrigelTM (Promega, Southampton, U.K.), control plasma (Sigma, Poole, U.K.), Dulbecco's modified Eagle's medium (DMEM) supplemented with GlutamaxTM, PBS, trypsin/EDTA and foetal calf serum (FCS) (all from Gibco BRL, Paisley, U.K.). Synthetic KRAD14 peptide (Lys-Ala-Gln-SerLys-Lys-Asn-Lys-His-Arg-His-Ser-Ile-Thr) was purchased to order (Genosys Biotechnologies, Cambridge, U.K.). A control peptide, derived from an alternate region of apoBlOO (residues 3358-3372;
Thr-Arg-Leu-Thr-Arg-Lys-ArgGly-Leu-Lys-Leu-Ala-Thr-Ala-Leu), was purchased from Sigma. T h e control antibody that was directed against Aspergillus nidulans glucose oxidase was purchased from Dako, High Wycombe, Bucks., U.K., and the TF85G9 antibody was provided by Professor Wolfram Ruf, Department of Immunology and Vascular Biology, T h e Scripps Research Institute, La Jolla, CA, U.S.A.
Culture of cells on MatrigelTM
MatrigelTM (50 pl) was used to coat the bottom of each well of 24-well tissue culture dishes. MatrigelTM-coated wells were incubated at 37 "C for 60 min to allow polymerization of the matrix.
T24 cells were harvested using trypsin/ EDTA solution and were washed with PBS containing 5 o/ o FCS. Cells (5 x lo4) that were resuspended in 0.5 ml of DMEM containing GlutamaxTM and 5 % FCS were added into each well. Inhibitors of TF activity, the KRAD14 peptide or the TF85G9 antibody, were added to the culture wells at the desired final concentrations. For the controls, cells were incubated with the control peptide or the control antibody. Cells were cultured at 37 "C in a humidified incubator containing 5 yo CO, for 24 h prior to the determination of network density.
Determination of density of cellular networks
T h e total number of networks, defined as a cellfree area bounded on all sides by cells, i.e. a hole in the network structure, was determined. Mathematical validation that the number of holes is an index of the density of network structures is given. T h e typical area per hole (A,) is given by
where XA is the total area of the culture dish and XN is the total number of holes.
Given that the cellular boundaries between the holes is small and the sample is sufficiently large, the number of cell intersections is proportional to the density of the networks. Therefore, the typical distance between two cell intersections (R) is of the order
Thus, the number of cell intersections per unit area (density) is given by 1/R2 = XN/XA Since Z A is constant, XN is inversely proportional to the distance between cell intersections (R2).
Thus, the total number of holes per well is an index of the density of cellular networks.
Statistical analysis
Results are expressed as means f S.E.M. for triplicate cultures in four independent experiments. Differences between treatment groups and control cultures were assessed using the paired Student's t test. Differences among means were considered as significant at P < 0.05.
Results

Inhibition of network formation by KRAD I 4 peptide
T h e KRAD14 peptide (0.01-1 pM) was added to cultures to determine the effects on the density of network formation. For the controls, the control peptide was added to the cultures. As shown in oxidase had no effect upon the formation of networks in the culture system.
The TF85G9 antibody or the control antibody (anti-glucose oxidase. Aspergillus nidulans) was added at the desired final concentrations. The cultures were scored for the density of network formation as described in the Materials and methods. Results are given as meanfS.E.M. and represent four independent KRAD14 peptide to inhibit the procoagulant activity of TF by preventing the activation of FVII by TF [31] . Inhibition of network formation is likely to be mediated by the ability of KRAD14 -experiments.
to prevent activation of FVII by TF.
-
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Mechanism of inhibition of FVll activation by KRAD I 4 peptide
We have previously investigated the mechanism of inhibition of TF by KRADl4 [31] . The apoB100-derived peptide is derived from a domain involved in binding to the L D L receptor (LDLR). Furthermore, residues 56-66 of TF are structurally similar to an LDL-binding domain in the LDLR. We propose that the KRAD14 peptide interacts with Rotation of the protease head of FVII is probably dependent upon immobilization of FVII by these bonds. T h e hydrogen bonds between FVII and residues G I u~~ and Asp5' in the proposed KRADbinding site of TF are the closest hydrogen bonds to the rotation site. Since we suspect that the KRADl4 peptide binds G~u~~ and the KRAD14 peptide has the potential to inhibit FVII activation by T F .
Development of KRAD I 4 peptide as a therapeutic compound
Microvessel density in breast cancer is prognostic indicator of metastatic risk [22] . Furthermore, angiogenesis is implicated in the progression of atherosclerotic plaques [16] [17] [18] [19] [20] [21] 29, 30, 3437] . Since TF activity is required for the induction of angiogenesis [24-281, inhibition of TF activity represents a therapeutic target for the prophylactic treatment of metastasis (reviewed in [38] ) and atherosclerosis.
T h e therapeutic benefit of inhibition of TF activity in the prevention of metastasis and plaque progression has been substantiated. Nilsson et al. [39] have demonstrated that inhibition of TF activity in tumour vasculature promotes infarction of teratocarcinoma in nude mice. In addition, inhibition of TF activity with TF pathway inhibitor attenuates intimal hyperplasia and restenosis in models of arterial injury [40, 41] . Furthermore, inhibitors of angiogenesis have been shown to reduce plaque growth in apoE-deficient mice [29] . We therefore propose that a stable counterpart of the KRAD14 peptide may be useful in the development of a pharmaceutical reagent for the treatment of diseases whose pathologies are related to the induction of angiogenesis, including tumour metastasis, myocardial infarction, stroke and diabetic retinopathy.
